Back

Prognostic impact of residual symptoms at discharge in patients hospitalized for worsening heart failure

30 August 2025 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Novel insight into heart failure Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Yu Yamada

Yokohama City University Hospital, Yokohama (Japan)

6 More presentations in this session

Presentation thumbnail
The impact of early SGLT2i inclusion in quadruple therapy for de novo patients: enhancing medication management and clinical outcomes
Doctor A. Esteban Fernandez (Leganes, ES)
Abstract Slides Video
Presentation thumbnail
Current status and characteristics of advance directives in Japanese patients with acute heart failure
Doctor K. Takabayashi (Shiga, JP)
Abstract Slides Video
Presentation thumbnail
Safety and efficacy of Vericiguat 5mg initiation in combination with guideline-directed medical therapy in the treatment of Heart failure with reduced ejection fraction
Professor Y. Wang (Changchun, CN)
Abstract Slides Video
Presentation thumbnail
Oral acetazolamide in acute heart failure: effects on renal function and clinical outcomes
Mr J. Gomez Rosero (Medellin, CO)
Abstract Slides Video
Presentation thumbnail
Characteristics and treatment of patients with heart failure followed in heart failure units in Spain. Differences according to the type of unit.
Doctor A. Esteban Fernandez (Leganes, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Novel insight into heart failure

The Event

Event poster

ESC Congress 2025

30 August 2025 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Prognostic impact of symptom relief under low and normal physical performance in patients hospitalized for worsening heart failure
thumbnail
Congress Presentation
Prognostic impact of patterns of in-hospital heart failure on clinical outcomes after myocardial infarction
thumbnail
Congress Presentation
Heart failure early post discharge appointment: a 2.5-year single-center experience

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources